# Akston Biosciences Corporation.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akston-biosciences

- Industry: Biotechnology
- Headquarters: Beverly, US
- Website: www.akstonbio.com
- Latest round: Series E (Apr 4, 2019)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2011 by Todd Zion (CEO), and others, Akston Biosciences Corporation, is a biotechnology company that leverages its novel fusion protein platform to develop and manufacture new classes of biologics. In March 2022, Akston Biosciences Corporation. raised USD 5.1 million in venture funding from investors. Akston, along with the Strides Group's Biolexis Private Limited manufactures and commercializes covid vaccines AKS-452 in India and over 130 countries in Asia, Latin America, and Africa. The firm has also collaborated with Dechra Pharmaceuticals PLC (DPH) to commercialize insulin therapies for canines and felines.

The firm employs its proprietary Fc-fusion platform to develop therapeutic antibodies that specifically tailor the different components of a moiety to optimize its performance and manufacturability to help treat a wide variety of diseases.  The therapeutic companies thus created can be produced on a large scale using techniques and tools that are industry standard for producing biologics including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.

## Funding rounds

- Series E, Apr 4, 2019 — Boston Harbor Angels, Formation Venture Engineering

## Investors

- Boston Harbor Angels — Series E
- Formation Venture Engineering (https://capitalatlas.ai/funds/formation-venture-engineering) — Series E